Larvol Delta - Mipletamig-Delivers-Compelling-86-Clinical-Benefit-Rate-and-No-CRS-as-Evaluable-AML-Patient-Data-increases-by-Nearly-50

mipletamig (APVO436) - Aptevo Therap

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mipletamig-delivers-compelling-86-clinical-benefit-rate-and-no-crs-as-1145581

Mar 10, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next